Nektar Therapeutics (Nasdaq: NKTR) is 6% higher in early action as EU Exubera opinion expected today. An analyst at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE